Literature DB >> 24582101

Relationships between diabetes and cognitive impairment.

Suzanne M de la Monte1.   

Abstract

Epidemics of obesity, diabetes, nonalcoholic fatty liver disease, and cognitive impairment/Alzheimer disease have emerged over the past 3 to 4 decades. These diseases share in common target-organ insulin resistance with a constellation of molecular and biochemical abnormalities that lead to organ/tissue degeneration over time. This article discusses the fundamental links among these diseases and how peripheral organ insulin resistance diseases contribute to cognitive impairment and neurodegeneration. A future role of endocrinologists and diabetologists could be to provide integrative diagnostic and treatment approaches for this collection of diseases that seem to share pathophysiological and pathogenetic bases.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer disease; Cognitive impairment; Diabetes; Insulin resistance; Insulin sensitizers; Neurodegeneration; Obesity

Mesh:

Year:  2013        PMID: 24582101      PMCID: PMC4978517          DOI: 10.1016/j.ecl.2013.09.006

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  141 in total

1.  Dysfunctional pro-ceramide, ER stress, and insulin/IGF signaling networks with progression of Alzheimer's disease.

Authors:  Suzanne M de la Monte; Edward Re; Lisa Longato; Ming Tong
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

2.  Nitrosamine exposure causes insulin resistance diseases: relevance to type 2 diabetes mellitus, non-alcoholic steatohepatitis, and Alzheimer's disease.

Authors:  Ming Tong; Alexander Neusner; Lisa Longato; Margot Lawton; Jack R Wands; Suzanne M de la Monte
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

3.  A visual [18F]FDG-PET rating scale for the differential diagnosis of frontotemporal lobar degeneration.

Authors:  Stefan Poljansky; Bernd Ibach; Barbara Hirschberger; Peter Männer; Hans Klünemann; Göran Hajak; Jörg Marienhagen
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-01-05       Impact factor: 5.270

Review 4.  Incretin analogues that have been developed to treat type 2 diabetes hold promise as a novel treatment strategy for Alzheimer's disease.

Authors:  Christian Holscher
Journal:  Recent Pat CNS Drug Discov       Date:  2010-06

Review 5.  Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer's disease.

Authors:  Lisa Mosconi; Alberto Pupi; Mony J De Leon
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

6.  Mechanisms of ceramide-mediated neurodegeneration.

Authors:  Ming Tong; Suzanne M de la Monte
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

7.  Cerebral excess release of neurotransmitter amino acids subsequent to reduced cerebral glucose metabolism in early-onset dementia of Alzheimer type.

Authors:  S Hoyer; R Nitsch
Journal:  J Neural Transm       Date:  1989       Impact factor: 3.575

Review 8.  How does parkin ligate ubiquitin to Parkinson's disease?

Authors:  Philipp J Kahle; Christian Haass
Journal:  EMBO Rep       Date:  2004-07       Impact factor: 8.807

Review 9.  Free fatty acids and skeletal muscle insulin resistance.

Authors:  Edward W Kraegen; Gregory J Cooney
Journal:  Curr Opin Lipidol       Date:  2008-06       Impact factor: 4.776

Review 10.  Altered lipid metabolism in brain injury and disorders.

Authors:  Rao Muralikrishna Adibhatla; J F Hatcher
Journal:  Subcell Biochem       Date:  2008
View more
  30 in total

Review 1.  Insulin resistance, dyslipidemia, and apolipoprotein E interactions as mechanisms in cognitive impairment and Alzheimer's disease.

Authors:  Therese S Salameh; Elizabeth M Rhea; William A Banks; Angela J Hanson
Journal:  Exp Biol Med (Maywood)       Date:  2016-07-28

Review 2.  Insulin Resistance and Neurodegeneration: Progress Towards the Development of New Therapeutics for Alzheimer's Disease.

Authors:  Suzanne M de la Monte
Journal:  Drugs       Date:  2017-01       Impact factor: 9.546

Review 3.  Gut-brain connection: The neuroprotective effects of the anti-diabetic drug liraglutide.

Authors:  Emanuel Monteiro Candeias; Inês Carolina Sebastião; Susana Maria Cardoso; Sónia Catarina Correia; Cristina Isabel Carvalho; Ana Isabel Plácido; Maria Sancha Santos; Catarina Resende Oliveira; Paula Isabel Moreira; Ana Isabel Duarte
Journal:  World J Diabetes       Date:  2015-06-25

Review 4.  Insulin resistance takes center stage: a new paradigm in the progression of bipolar disorder.

Authors:  Cynthia V Calkin
Journal:  Ann Med       Date:  2019-08-27       Impact factor: 4.709

Review 5.  Targeting Mitochondria in Alzheimer Disease: Rationale and Perspectives.

Authors:  Chiara Lanzillotta; Fabio Di Domenico; Marzia Perluigi; D Allan Butterfield
Journal:  CNS Drugs       Date:  2019-10       Impact factor: 5.749

Review 6.  Targeting the prodromal stage of Alzheimer's disease: bioenergetic and mitochondrial opportunities.

Authors:  Charles C Caldwell; Jia Yao; Roberta Diaz Brinton
Journal:  Neurotherapeutics       Date:  2015-01       Impact factor: 7.620

Review 7.  Diabetes mellitus and cognitive impairments.

Authors:  Elham Saedi; Mohammad Reza Gheini; Firoozeh Faiz; Mohammad Ali Arami
Journal:  World J Diabetes       Date:  2016-09-15

8.  Amyloid-β pathology and APOE genotype modulate retinoid X receptor agonist activity in vivo.

Authors:  Leon M Tai; Kevin P Koster; Jia Luo; Sue H Lee; Yue-Ting Wang; Nicole C Collins; Manel Ben Aissa; Gregory R J Thatcher; Mary Jo LaDu
Journal:  J Biol Chem       Date:  2014-09-12       Impact factor: 5.157

Review 9.  Elevated risk of type 2 diabetes for development of Alzheimer disease: a key role for oxidative stress in brain.

Authors:  D Allan Butterfield; Fabio Di Domenico; Eugenio Barone
Journal:  Biochim Biophys Acta       Date:  2014-06-17

10.  EEG spectral power abnormalities and their relationship with cognitive dysfunction in patients with Alzheimer's disease and type 2 diabetes.

Authors:  Christopher S Y Benwell; Paula Davila-Pérez; Peter J Fried; Richard N Jones; Thomas G Travison; Emiliano Santarnecchi; Alvaro Pascual-Leone; Mouhsin M Shafi
Journal:  Neurobiol Aging       Date:  2019-10-14       Impact factor: 4.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.